



Message to the PKP2-ACM Community

Dear Advocacy Partners,

This morning, we shared a press release that includes some updates about our investigational gene therapy candidate, LX2020, for the treatment of PKP2 arrhythmogenic cardiomyopathy. We are pleased to share some exciting developments on our program, which you can read below.

You can read the full press release [here](#) on the Lexeo website.

Highlights include:

- Data to date from two participants in cohort 1 of our Phase 1/2 clinical trial show
 - 71% and 115% increases in PKP2 protein levels from the individuals' starting levels
 - A 67% reduction in premature ventricular contractions (PVCs) at 6 months after gene therapy administration in the first participant. PVCs are irregular heartbeats, and having a high number of PVCs over time can increase your risk for certain heart complications.
- Completed enrollment of cohort 2 (higher dose cohort) in the LX2020 HEROIC-PKP2 Phase 1/2 trial, including three participants
- We plan to share more clinical data from our Phase 1/2 trial for LX2020 by the end of this year
- LX2020 continues to be generally well tolerated by study participants. No serious side effects related to the study drug have been observed to date
- The European Commission has granted LX2020 orphan medicinal product designation, which could lead to faster development and more frequent touchpoints with the European Medicines Agency (EMA)

We greatly appreciate our study investigators and the courageous trial participants and caregivers who have helped us get to this point.

We will keep this community updated as we continue our work with regulatory authorities to design and implement clinical studies, as well as enroll participants in

ongoing and future trials. For more information or any questions, please contact clinicaltrials@lexeotx.com.

Thank you for your partnership and for working with us to advance research to address the unmet need in PKP2-ACM.

The Lexeo Team